
Novartis’ Kisqali combo rejected by NICE for advanced breast cancer
pharmafile | April 11, 2019 | News story | Sales and Marketing |Â Â Kisqali, NHS, NICE, Novartis, pharmaÂ
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, the organisation has announced.
Specifically, the drug was turned down in combination with fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in patients who have had previous endocrine therapy.
Despite clinical data demonstrating that the drug combo improved progression-free survival compared to fulvestrant alone in treatment naĂŻve patients and in patients following endocrine treatment, data on overall survival benefit were not sufficiently mature, meaning cost-effectiveness estimates were calculated much higher than the range NICE considers an acceptable use of NHS resources.
As a result, NICE judged that the combo does not have “plausible potential to be cost-effective at the offered price” and could not recommend its use on the NHS, though noted that additional data may address the uncertainties in the provided data.
Patients in the this indication can access Verzenio (abemaciclib) with fulvestrant via the Cancer Drugs Fund, and Kisqali is recommended by NICE in combination with an aromatase inhibitor for previously untreated hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Public consultation is open on the decision until 9 May 2019.
Matt Fellows
Related Content

NHS spends ÂŁ240m storing patient records as digital reforms gather pace
The NHS spent almost ÂŁ240m storing patient records in 2024/25, according to analysis by The …

NHS awards national diabetes education contract to Leicester programme
University Hospitals of Leicester NHS Trust (UHL) has been awarded a five-year contract to deliver …

Product value to pathway impact: What the CVD Modern Service Framework means for pharma
By Sabina Syed and Ewan Maule The Cardiovascular Disease Modern Service Framework1(CVD MSF) begins with a …




